Evidence map›Paper›PMID 36609129›Full record

ReviewEpilepsy & behavior : E&B2023

Why ketamine.

Lisa Coles, Eric S Rosenthal, Thomas P Bleck, Jordan Elm, Shahriar Zehtabchi, James Chamberlain, James Cloyd, Shlomo Shinnar, Robert Silbergleit, Jaideep Kapur

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Epilepsy & behavior : E&B, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Intramuscular Ketamine Pharmacokinetics in Humans: A Review.European journal of drug metabolism and pharmacokinetics · 2026
    Review
  2. Article
  3. Review
  4. Article
  5. Strategies to innovate emergency care of status epilepticus.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Review
  6. Ketamine reduces seizure and interictal continuum activity in refractory status epilepticus: a multicenter in-person and teleneurocritical care study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024
    Article
  7. Status epilepticus in the ICU.Intensive care medicine · 2024
    Review
  8. Ketamine, an Old-New Drug: Uses and Abuses.Pharmaceuticals (Basel, Switzerland) · 2023
    Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 9 institutions in 1 country.

Lisa ColesCenter for Orphan Drug Research, Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN, United States.
Eric S RosenthalDepartment of Neurology, Massachusetts General Hospital, Boston, MA, United States.
Thomas P BleckDepartment of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.
Jordan ElmDepartment of Public Health Sciences, Medical University of South Carolina, Charleston, SC, United States.
Shahriar ZehtabchiDepartment of Emergency Medicine, Downstate Health Sciences University, Brooklyn, NY, United States.
James ChamberlainDivision of Emergency Medicine, Children's National Hospital Washington, DC, United States.
James CloydCenter for Orphan Drug Research, Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN, United States.
Shlomo ShinnarDepartments of Neurology, Pediatrics, Epidemiology and Public Health, Albert Einstein College of Medicine, Bronx, NY, United States.
Robert SilbergleitDepartment of Emergency Medicine, University of Michigan, School of Medicine, Ann Arbor, MI, United States.
Jaideep KapurDepartment of Neurology and Neuroscience, University of Virginia, School of Medicine, Charlottesville, VA, United States. Electronic address: jk8t@virginia.edu.
University of Minnesota · USAlbert Einstein College of Medicine · USChildren's National · USMassachusetts General Hospital · USMedical University of South Carolina · USMichigan Medicine · USNorthwestern University · USSUNY Downstate Health Sciences University · USUniversity of Virginia · US

Funding

TREATMENT OF STATUS EPILEPTICUSR01NS040337 · NINDS · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI KAPUR, JAIDEEP · 2000 to 2021
$5.0M
Motor cortex plasticity in temporal lobe epilepsyR01NS120945 · NINDS · UNIVERSITY OF VIRGINIA · PI KAPUR, JAIDEEP · 2021 to 2025
$2.5M
NINDS NIH HHS R01 NS040337NINDS NIH HHS R01 NS120945
6 · The paper itself

Abstract

We present the rationale for testing ketamine as an add-on therapy for treating benzodiazepine refractory (established) status epilepticus. In animal studies, ketamine terminates benzodiazepine refractory status epilepticus by interfering with the pathophysiological mechanisms and is a neuroprotectant. Ketamine does not suppress respiration when used for sedation and anesthesia. A Series of reports suggest that ketamine can help terminate refractory and super refractory status epilepticus. We propose to use 1 or 3 mg/Kg ketamine intravenously based on animal-to-human conversion and pharmacokinetic studies. This paper was presented at the 8th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures held in September 2022.

Indexed as

KetamineNeuroprotective AgentsStatus EpilepticusAnticonvulsantsBenzodiazepinesHumansSeizuresAnticonvulsantsBenzodiazepinesKetamineNeuroprotective AgentsEstablished status epilepticusNeuroprotectionNMDA receptorPharmacokinetics

Identifiers

PMID36609129
PMCPMC10073319
OpenAlexW4313593011

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.